The 4D randomized clinical trial, a multicenter, double-blind, placebo-controlled study conducted across nine ICUs, investigated the effectiveness of continuous intravenous dexmedetomidine infusion versus placebo in non-intubated critically ill adults suffering from hyperactive delirium.

The trial’s primary focus was to assess the clinical benefit of the drug based on a joint modeling of multiple outcomes, including agitation control, delirium resolution, and the need for intubation with mechanical ventilation.

The results demonstrated that the use of dexmedetomidine was associated with a greater overall clinical benefit compared to placebo. Specifically, dexmedetomidine significantly reduced the median duration of agitation by approximately one hour in these patients.

This evidence suggests that dexmedetomidine is a valuable therapeutic alternative for managing hyperactive delirium in non-intubated intensive care unit patients.

Read More